American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (899)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1242)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (46)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4954)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5326)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Heterogeneity in access and toxicity management of commercially available BCMA-directed CAR-T and Bispecific T-cell engager therapy among the international myeloma community
    Meeting Abstract

    Hassan, H.; Samur, M. K.; Cohen, A. D.; Moreau, P.; Otero, P. R.; Kumar, S. K.; Mateos, M. V.; Avigan, D.; Sperling, A. S.; Nadeem, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population
    Meeting Abstract

    Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • EBV prevalence and overall survival in the Multi Ethnic Study of Hodgkin lymphoma (MESH)
    Meeting Abstract

    Lam, E.; Wan, J. Y.; Aparicio, J.; Pullarkat, S.; Colombo, A.; Song, J. Y.; Chao, C.; Mejia-Arangure, J. M.; Hernandez, B.; Jiang, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CNS prophylaxis in adult ALL patients after stem cell transplantation: An EBMT survey on general practice
    Meeting Abstract

    Chiusolo, P.; Labopin, M.; Khvedelidze, I.; Baron, F.; Brissot, E.; Bazarbachi, A.; Bug, G.; Esteve, J.; Giebel, S.; Gorin, N. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET4 response as an independent predictor of long-term outcomes in ECHELON2 (A+CHP vs. CHOP) in CD30+PTCL
    Meeting Abstract

    Iyer, S. P.; Mehta-Shah, N.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domenech, E. D.; Pagani, C.; Kim, W. S.; Alpdogan, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • AHOD2131: A randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma
    Meeting Abstract

    Henderson, T. O.; Hu, B.; Keller, F.; Pei, Q.; Wu, Y.; Hoppe, B.; Milgrom, S.; Yao, S.; Khan, N.; Roth, L. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1 study of KTX-1001, an oral, first-in-class, selective MMSET inhibitor in patients with relapsed and refractory multiple myeloma
    Meeting Abstract

    Berdeja, J. G.; Dingli, D.; Lonial, S.; Yee, A. J.; Chung, A.; Gasparetto, C.; Bergsagel, P. L.; Roy, V.; Abdallah, A. O.; Thanendrarajan, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The impact of melphalan conditioning schedule on post-transplant outcomes in AL amyloidosis: A multicenter study with 1718 patients
    Meeting Abstract

    Muchtar, E.; Sanchorawala, V.; Hassan, H.; Hegenbart, U.; Schonland, S.; Lee, H. C.; Qazilbash, M. H.; Kin, A.; Houde, C. A.; Buadi, F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Hepatic response and progression criteria in light chain amyloidosis: A multicenter validation study
    Meeting Abstract

    Muchtar, E.; Palladini, G.; Schonland, S.; Dispenzieri, A.; Wisniowski, B.; Merlini, G.; Milani, P.; Hegenbart, U.; Dittrich, T.; Kastritis, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Anti-leukemic activity of Luveltamab tazevibulin (LT, STRO-002), a novel Folate receptor-α (FR-α)-targeting antibody drug conjugate (ADC) in relapsed/refractory CBF2AT3::GLIS2 AML
    Meeting Abstract

    Williams, R.; Miller, L.; Massaro, S.; Krieger, E.; Pauly, M.; Nelson, C.; Johnson, R.; Welch, J. J. G.; Bhojwani, D.; Moghimi, B.; more...
    Blood (2023)

    Fulltext@MSK | Save